Patisiran, an Investigational RNAi Therapeutic for Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Polyneuropathy: Results from the Phase 3 APOLLO study (CT.001)
Neurology | December 7, 2023 | Volume: 90 | Issue: 15_supplement | Pages: No page available
10.1212/wnl.90.15_supplement.ct.001